ASP Isotopes Stocks Decline Following Fuzzy Panda Research Report

On Tuesday, ASP Isotopes (ASPI) shares fell by 20% following a critical report from Fuzzy Panda Research. The report claims that ASPI is using outdated laser enrichment technology and is linked to individuals previously accused of securities fraud.

Fuzzy Panda Research alleges that ASPI presents itself as a new and innovative uranium enrichment company, but in reality, it employs old and uneconomical technology. The report asserts that based on interviews with former executives from customers and competitors, ASPI's technology is nearly worthless. It also states that ASPI's technology was once considered for acquisition by Centrus but was rejected because it was not even valued at $2 million.

The report further raises concerns about ASPI's lack of patents. The company claims that patents would be detrimental and that its processes are a trade secret. Additionally, the report highlights the company's dubious history, noting its establishment in September 2021 and subsequent funding by a shell company linked to individuals previously accused of securities fraud.

Fuzzy Panda Research's investigation could not identify multiple affiliates registered at ASPI's addresses in South Africa. The report also mentions that ASPI's AVLIS technology for laser enrichment of uranium was shelved by twenty governments after decades of research due to its lack of economic viability.

Experts are also voicing doubts about ASPI's ability to obtain an NRC license for uranium enrichment, pointing out that this process could take up to 15 years. They also contest the company's cost estimates for building facilities, suggesting that real costs, which ASPI claims are under $10 million, could actually reach billions.

The report concludes by asserting that ASP Isotopes could be the most extreme example of a paid stock promotion based on outdated technology, demonstrating that government research is commercially unviable.